A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors
Latest Information Update: 13 Oct 2023
At a glance
- Drugs BAT 1308 (Primary) ; BAT 6021 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bio-Thera Solutions
- 09 Oct 2023 Status changed from recruiting to discontinued.
- 16 Mar 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.
- 24 Jan 2022 According to BioThera Solutions media release, first patient has been Dosed in this study.